Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease
- 175 Downloads
Laquinimod, an immunomodulatory agent under clinical development for Huntington disease (HD), has recently been shown to confer behavioural improvements that are coupled with prevention of atrophy of the white matter (WM)-rich corpus callosum (CC) in the YAC128 HD mice. However, the nature of the WM improvements is not known yet. Here we investigated the effects of laquinimod on HD-related myelination deficits at the cellular, molecular and ultrastructural levels. We showed that laquinimod treatment improves motor learning and motor function deficits in YAC128 HD mice, and confirmed its antidepressant effect even at the lowest dose used. In addition, we demonstrated for the first time the beneficial effects of laquinimod on myelination in the posterior region of the CC where it reversed changes in myelin sheath thickness and rescued Mbp mRNA and protein deficits. Furthermore, the effect of laquinimod on myelin-related gene expression was not region-specific since the levels of the Mbp and Plp1 transcripts were also increased in the striatum. Also, we did not detect changes in immune cell densities or levels of inflammatory genes in 3-month-old YAC128 HD mice, and these were not altered with laquinimod treatment. Thus, the beneficial effects of laquinimod on HD-related myelination abnormalities in YAC128 HD mice do not appear to be dependent on its immunomodulatory activity. Altogether, our findings describe the beneficial effects of laquinimod treatment on HD-related myelination abnormalities and highlight its therapeutic potential for the treatment of WM pathology in HD patients.
KeywordsHuntington disease Behaviour Laquinimod White matter Oligodendroglia Myelination
Microscopy images for this study were acquired at the SBIC-Nikon Imaging Centre (Biopolis, Singapore).
M.G.M. designed and performed experiments, data analysis and interpretation, and wrote the manuscript. N.A.B.M.Y., J.Y.T., C.R., H.S. and L.J.T. performed experiments. N.Z. and M.R.H. contributed to the study design and revision of the manuscript. M.A.P. conceived and designed experiments, participated in analysis and interpretation of data, and wrote the manuscript.
This study was supported by a grant from Teva Pharmaceuticals. M.A.P. is supported by a Strategic Positioning Fund for Genetic Orphan Diseases (SPF2012/005) from the Agency for Science Technology and Research, and by the National University of Singapore, Singapore.
Compliance with Ethical Standards
Conflict of Interest
N.Z., H.B. and M.R.H. are employees of Teva Pharmaceuticals, and contributed to the study design and revision of the manuscript. Teva Pharmaceuticals played no role in the treatment or testing of animals, or the collection, analysis and interpretation of the results.
- 1.Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, et al. (2015) Huntington disease. Nat Rev Dis Primers 15005. doi: https://doi.org/10.1038/nrdp.2015.5
- 7.Pavese N, Gerhard A, Tai YF, Ho AK, Turkheimer F, Barker RA, Brooks DJ, Piccini P (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66:1638–1643. https://doi.org/10.1212/01.wnl.0000222734.56412.17 CrossRefPubMedGoogle Scholar
- 8.Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med 205:1869–1877. https://doi.org/10.1084/jem.20080178 CrossRefPubMedPubMedCentralGoogle Scholar
- 9.Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ, Tabrizi SJ, Barker RA et al (2011) Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp 32:258–270. https://doi.org/10.1002/hbm.21008 CrossRefPubMedGoogle Scholar
- 10.Politis M, Lahiri N, Niccolini F, Su P, Wu K, Giannetti P, Scahill RI, Turkheimer FE et al (2015) Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol Dis 83:115–121. https://doi.org/10.1016/j.nbd.2015.08.011 CrossRefPubMedGoogle Scholar
- 14.Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS et al (2016) Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. PNAS 113:E6145–E6152. https://doi.org/10.1073/pnas.1607843113 CrossRefPubMedGoogle Scholar
- 15.Aharoni R, Saada R, Eilam R, Hayardeny L, Sela M, Arnon R (2012) Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 251:14–24. https://doi.org/10.1016/j.jneuroim.2012.06.005 CrossRefPubMedGoogle Scholar
- 17.Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S et al (2016) Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep 6:31652. https://doi.org/10.1038/srep31652 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X et al (2017) Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight 2. https://doi.org/10.1172/jci.insight.95665
- 21.Paxinos G, Franklin KB (2012) Paxinos and franklin's the mouse brain in stereotaxic coordinates. Academic PressGoogle Scholar
- 23.Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W et al (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum Mol Genet 21:2219–2232. https://doi.org/10.1093/hmg/dds037 CrossRefPubMedGoogle Scholar
- 25.Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR et al (2005) Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease. J Neurosci 25:4169–4180. https://doi.org/10.1523/JNEUROSCI.0590-05.2005 CrossRefPubMedGoogle Scholar
- 27.Teo RTY, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L et al (2016) Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Hum Mol Genet 25:2621–2632. https://doi.org/10.1093/hmg/ddw122 CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Xiang Z, Valenza M, Cui L, Leoni V, Jeong HK, Brilli E, Zhang J, Peng Q et al (2011) Peroxisome-proliferator-activated receptor gamma coactivator 1 α contributes to dysmyelination in experimental models of Huntington’s disease. J Neurosci 31:9544–9553. https://doi.org/10.1523/JNEUROSCI.1291-11.2011 CrossRefPubMedPubMedCentralGoogle Scholar
- 32.Jin J, Peng Q, Hou Z, Jiang M, Wang X, Langseth AJ, Tao M, Barker PB et al (2015) Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington’s disease. Hum Mol Genet 24:2508–2527. https://doi.org/10.1093/hmg/ddv016 CrossRefPubMedPubMedCentralGoogle Scholar